Coronavirus disease 2019 caused by SARS-CoV-2. Multiple vaccine platforms were developed at unprecedented speed, with mRNA vaccines representing a breakthrough in vaccine technology.
COVID-19 is a respiratory illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). First identified in Wuhan, China in December 2019, it quickly spread globally and was declared a pandemic by WHO on March 11, 2020 (WHO, 2020).
Symptoms range from mild (fever, cough, fatigue) to severe (pneumonia, acute respiratory distress syndrome, multi-organ failure). Older adults and those with underlying health conditions are at higher risk for severe illness. As of 2026, COVID-19 continues to circulate as an endemic respiratory virus. Under the January 2026 federal schedule reorganization, COVID-19 vaccination for children transitioned to the Shared Clinical Decision-Making (SCDM) tier.
Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax). Deliver mRNA instructions for cells to produce spike protein, triggering immune response. Novel platform, 95% efficacy initially.
Johnson & Johnson's Janssen and AstraZeneca. Use harmless virus to deliver spike protein gene. Single dose option, 66-72% efficacy.
Novavax. Contain purified spike proteins with adjuvant. Traditional technology, ~90% efficacy. Storage at refrigerator temperatures.
Sinovac (CoronaVac), Sinopharm. Whole virus inactivated with adjuvant. Widely used globally, efficacy varies by study.
Next-generation evolution of mRNA technology. saRNA contains genetic instructions for both the target antigen and the molecular machinery to replicate itself inside the cell, allowing for lower initial doses while potentially producing stronger immune responses. As of early 2026, saRNA vaccine candidates for COVID-19 and other respiratory diseases are under clinical evaluation but have not yet received full FDA licensure.
Vaccination remains the most effective strategy for preventing severe COVID-19. The following describes established medical consensus for clinical management for those who contract infection.
For high-risk individuals, antiviral therapy with Nirmatrelvir/Ritonavir (Paxlovid) or Molnupiravir is recommended to reduce risk of severe disease. Critical warning: Paxlovid has significant drug-drug interactions and is contraindicated with many common medications — prescribers must conduct a full medication review before prescribing. For mild cases in low-risk individuals, supportive care (rest, hydration, fever management) is appropriate.
Disclaimer: This information is for educational purposes only. Treatment decisions must be made by a qualified healthcare provider.